LipoTrust™ EX Oligo for in vitro - Cosmo Bio Co.,Ltd.

Antibodies

>

LipoTrust™ EX Oligo for in vitro

Catalog No.: CSR-LEO-01-EX
Size: 1ML
[1ƒĘmol]
Price: ¥46200
$616
Storage: 4C
@
Purpose: Transfection reagent for short oligonucleotides such as siRNA, antisense DNA or miRNA.
component: Lipo Trust™ Oligo for in vitro (Lyophilizate for 1ml) x 1
Instruction manual

Other:

 Background 
As most transfection reagents have little gene expression activity in serum-containing medium, use of serum-free medium is recommended. LipoTrust™ has enough gene expression activity in serum-containing medium as well, so that itcan be used in both type of experiments with or without serum either in vitro or in vivo.
Though general transfection reagents are known to be cytotoxic, LipoTrust™ causes much less cytotoxicity. Moreover, the product form, lyophilizate, makes it possible to choose from two types depend on your purpose. One is Coating Type, which is to be used by dissolving the empty LipoTrust™ with nucleic acid solution to reconstruct liposomal membrane without compromising effective nucleic acidretention. The other Lipoplex Type is the general type which is used by mixing the transfection reagent solution with nucleic acid solution.
LipoTrust™ EX Oligo is a proprietary cationic liposome formulation that facilitates highly efficient delivery of short oligonucleotides such as siRNA, antisense DNA or miRNA to mammalian cells. Lyophilized powder is supplied so that customers can select 2 types of application which are Lipoplex Type and Coating Type. Lypoplex Type utilizes mixing of both separately prepared liposome suspension and short oligonucleotides solution while Coating Type utilizes direct mixing of short oligonucleotides solution into lyophilized powder.
 Feature and advantages 
Higher knock-down efficiency is expected with low concentration of short oligonucleotide.
Transfection is available in the presence of serum.
Higher level transfection would be expected in vivo use with minimizing cytotoxicity.



 IMAGE1





Reference:

•  T Kato et al., Gene Therapy, 1-9 (2010)
•  Robert Langer et al., Nature Review siRNA delivery 129-138
•  Kammei Rai et al., 100th AACR in April 19 (2009)
•  Hum. Gene Ther., 10,947-955 (1999)
•  J. Control.Release,62,269-277 (1999)
•  Biochim.Biophys.Acta,1467,419-430 (2000)
•  J.Control.Release,69,139-148(2000)
•  J.Biochem.,128,989-998(2000)
•  Pharm.Res.,19,377-381 (2002)
•  J.Biochem.,131.533-540 (2002)
•  Hypertension,40,148-154 (2002)
•  PHARM TECH JAPAN, 19,419-433 (2003)
•  Biotherapy,18,353-360 (2004)
 
>